Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis

Hegedus, Olga; Rydén, Johan; Rehnberg, Ann-Sofie; Nilsson, Stefan; Hellström, Per M.

doi:10.1097/00042737-200205000-00008

Cited by 35 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When available, H. pylori status was based on histological biopsies. If H. pylori status was unknown, a C 14 -urea breath test (HeliprobeTM; Noster Systems AB, Stockholm, Sweden) [25] was performed. All patients were supplemented appropriately with intravenous IgG.…”

Section: Patientsmentioning

confidence: 99%

Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia

Desar¹,

Deuren

Sprong

et al. 2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe two major primary antibody deficiency disorders are X-linked hypogammaglobulinaemia (XLA) and common variable immunodeficiency (CVID). CVID patients have an elevated risk for gastric cancer and extra-nodal marginal zone lymphoma. Both diseases are associated with Helicobacter pylori infection. We investigated whether antibody deficiency leads to defective serum bactericidal activity against H. pylori. We also investigated the correlation with immunoglobulin (Ig)M levels and observed the terminal complement complex (TCC) activity. Sera of 13 CVID patients (four H. pylori positive), one patient with hyper-IgM syndrome, one patient with Good syndrome (both H. pylori positive), five XLA patients, four H. pylori seropositive controls, four H. pylori seronegative controls and a sample of pooled human serum (PHS) were incubated in vitro with bacterial suspensions of H. pylori for 30 min. After 72 h of culture, colony-forming units were counted. TCC formation was measured by enzyme-linked immunosorbent assay. We found that normal human serum is bactericidal for H. pylori, whereas heat-inactivated serum shows hardly any killing of H. pylori. Serum (1%) of hypogammaglobulinaemia patients has a decreased bactericidal activity against H. pylori. Helicobacter pylori-positive (HP + ) normal individuals show more than 90% killing of H. pylori, whereas CVID patients show 35% killing (P = 0·007) and XLA patients only 19% (P = 0·003). Serum (1%) of HP + volunteers showed significantly better killing compared with serum of H. pylori-negative (HP -) volunteers (P = 0·034). No correlation between (substituted) IgG levels and serum bactericidal activity was found, but a weak correlation between total serum IgM and serum bactericidal activity was found. In conclusion, serum bactericidal activity against H. pylori is decreased in patients with hypogammaglobulinaemia. Heat treatment of the serum abolished the bactericidal capacity, indicating that complement activity is essential for the bactericidal effect.

show abstract

Section: Patientsmentioning

confidence: 99%

Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia

Desar¹,

Deuren

Sprong

et al. 2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Patients exhaled into the breath card until its color indicator changed from orange to yellow. The breath samples were measured using the Heliprobe analyzer (Noster system), and the activity was counted for 250 s. Results were expressed as counts per minute (cpm) and counts <25 cpm were defi ned as Heliprobe 0 = not infected, counts between 25 cpm and 50 cpm as Heliprobe 1 = equivocal and counts >25 cpm as Heliprobe 2 = infected [8].…”

Section: Urea Breath Testmentioning

confidence: 99%

Could the simplified 14C urea breath test be a new standard in noninvasive diagnosis of Helicobacter pylori infection?

et al. 2008

View full text Add to dashboard Cite

show abstract

“…To avoid oral hydrolysis, these authors proposed to administer this amount in a capsule (200,215,344). The ingestion of citric acid is also used to sensitize the test (462) instead of the traditional test meal.…”

mentioning

confidence: 99%

Helicobacter pyloriDetection and Antimicrobial Susceptibility Testing

2007

View full text Add to dashboard Cite

SUMMARY The discovery of Helicobacter pylori in 1982 was the starting point of a revolution concerning the concepts and management of gastroduodenal diseases. It is now well accepted that the most common stomach disease, peptic ulcer disease, is an infectious disease, and all consensus conferences agree that the causative agent, H. pylori, must be treated with antibiotics. Furthermore, the concept emerged that this bacterium could be the trigger of various malignant diseases of the stomach, and it is now a model for chronic bacterial infections causing cancer. Most of the many different techniques involved in diagnosis of H. pylori infection are performed in clinical microbiology laboratories. The aim of this article is to review the current status of these methods and their application, highlighting the important progress which has been made in the past decade. Both invasive and noninvasive techniques will be reviewed.

show abstract

Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis

Abstract: The novel Heliprobe UBT, with either liquid or encapsulated 14C-urea, seems equi-efficacious to conventional UBT in fulfilling its role as the non-invasive gold standard for detection of H. pylori.

Cited by 35 publications

References 12 publications

Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia

Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia

Could the simplified 14C urea breath test be a new standard in noninvasive diagnosis of Helicobacter pylori infection?

Helicobacter pyloriDetection and Antimicrobial Susceptibility Testing

Contact Info

Product

Resources

About